| Literature DB >> 27784896 |
Kandai Nozu1, Yoshimi Nozu1, Keita Nakanishi1, Takao Konomoto2, Tomoko Horinouchi1, Akemi Shono1, Naoya Morisada1, Shogo Minamikawa1, Tomohiko Yamamura1, Junya Fujimura1, Koichi Nakanishi3, Takeshi Ninchoji1, Hiroshi Kaito1, Ichiro Morioka1, Mariko Taniguchi-Ikeda1, Igor Vorechovsky4, Kazumoto Iijima1.
Abstract
Gitelman syndrome (GS) is an autosomal recessive renal tubulopathy characterized by hypokalemic metabolic alkalosis with hypocalciuria and hypomagnesemia. GS clinical symptoms range from mild weakness to muscular cramps, paralysis or even sudden death as a result of cardiac arrhythmia. GS is caused by loss-of-function mutations in the solute carrier family 12 member 3 (SLC12A3) gene, but molecular mechanisms underlying such a wide range of symptoms are poorly understood. Here we report cryptic exon activation in SLC12A3 intron 12 in a clinically asymptomatic GS, resulting from an intronic mutation c.1669+297 T>G that created a new acceptor splice site. The cryptic exon was sandwiched between the L3 transposon upstream and a mammalian interspersed repeat downstream, possibly contributing to inclusion of the cryptic exon in mature transcripts. The mutation was identified by targeted next-generation sequencing of candidate genes in GS patients with missing pathogenic SLC12A3 alleles. Taken together, this work illustrates the power of next-generation sequencing to identify causal mutations in intronic regions in asymptomatic individuals at risk of developing potentially fatal disease complications, improving clinical management of these cases.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27784896 DOI: 10.1038/jhg.2016.129
Source DB: PubMed Journal: J Hum Genet ISSN: 1434-5161 Impact factor: 3.172